List of Imaging Companies in Massachusetts - 20

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

BioPAL is a biotechnology company that provides novel diagnostic tools to the life science community.

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

CellTivity Scientific is a medtech company pioneering real-time, intraprocedural cancer diagnostics through Dynamic Cell Imaging (DCI)—our proprietary technology that visualizes cellular metabolism to assess biopsy adequacy and detect suspicious activity on the spot. Our Mission Empowering the proceduralist to improve patient outcomes through better diagnostic cancer sampling. What We Do Our flagship system, Van Gogh™, delivers instant metabolic “heat maps” of freshly excised tissue—no stains, no cuts, and no delays. Designed for the proceduralist, it fits directly into existing bronchoscopy workflows, empowering clinicians with immediate insights into cellular metabolism at the point-of-care - without altering or destroying tissue samples. This is accomplished by capturing both cellular morphology and metabolic activity to confirm lesion-in-tool, reduce indeterminate biopsies, and improve diagnostic yield at the point-of-care. Why It Matters ⚡ Real-Time Insight: Evaluate biopsy quality instantly, without waiting for pathology. 🔬 Metabolism Illuminated: Capture what traditional imaging can’t—live, functional behavior at the cellular level. 🧠 Proceduralist Empowerment: Eliminate uncertainty mid-procedure and enable data-driven decisions, without disrupting workflow. 🏥 Preserves Tissue Integrity: Samples remain untouched for downstream histology and molecular analysis (e.g., NGS). 📈 Clinically Validated: Proven to increase diagnostic confidence, shorten procedure time, and outperform traditional ROSE.

Collagen Medical is a healthcare company that specializes in medical products and services related to collagen.

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

We manufacture Vision electrophysiology testing equipment for detecting eye diseases and sold mainly to hospital and eye doctors. Based in the USA, we create the leading solutions for electrophysiology for all your needs in hospitals, research and drug trials

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

Established in 1996 and located along Route 128 in MA, HAI Laboratories, Inc. is the only American manufacturer of clinical, eye bank and laboratory specular microscopes in operation today. We are also known for our advanced software systems for image processing and analysis, digital video slit lamps and high quality ophthalmic microsurgical instruments.

Surgical Planning Associates, Inc. is a medical technology company based in Boston, Massachusetts. They developed the HipInsight System, a mixed reality-based digital surgery platform specifically for total hip arthroplasty. This system is notable for being the first FDA-cleared mixed reality navigation technology for hip surgeries. The HipInsight System utilizes Microsoft HoloLens 2 to provide surgeons with real-time holographic visuals of patient-specific anatomy, instruments, and implants. It enhances surgical precision through personalized planning and intraoperative guidance, seamlessly integrating into existing surgical workflows. The system is compatible with Zimmer Biomet's premier hip implant systems, and the company has successfully supported over 11,000 hip replacement surgeries globally.

There are still broad swaths of uncharted territories concerning the role lipid core plaques play in heart disease. Now, you can achieve unparalleled insights with the Infraredx Dualpro IVUS+NIRS catheter and its accompanying Makoto Intravascular Imaging System, FDA-cleared to identify patients and plaques at an increased risk of MACE. For more information about the Makoto Imaging System or Dualpro IVUS+NIRS Catheter visit www.infraredx.com. Infraredx, a Nipro Company is now proud to offer the OKAY II Y-Connector to the US market. The number one selling Y-Connector in Japan is now available. Visit www.infraredx.com/technology/nipro-okay-ii/ to learn how you can reduce blood loss with the OKAY II Y-Connector.

Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications. The company aims to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind.

Navigation Sciences™ is a clinical-stage company developing the NaviSci™ System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical instruments to guide precise surgical resection by enabling for the first time, real-time in-vivo margin measurement. The system aims to improve surgical outcomes with cutting-edge technologies that – reduce recurrence risk and conserve lung function – shorten hospital length of stay and enhance surgical workflow.

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

For over 50 years, PSI has provided technology solutions and innovative products to our government and commercial customers. Our employee-owners continue to grow the company across a range of markets applying emerging science to important problems. We play an important role in the development and transition of advanced technology from the laboratory to commercial and government use. PSI has a highly interdisciplinary staff with advanced degrees in chemistry, biology, physics and applied physics, electrical, aeronautical, and mechanical engineering, and materials science. We are structured to enable cross-disciplinary collaboration between our scientists and engineers in order to develop solutions to our customers' technical problems. Our extensive laboratory and prototyping facilities as well as low rate production capability enable us to rapidly go from concept to advanced prototype, and then on to manufacturing. We couple this internal capability with our long heritage in field and clinical testing of prototype systems enabling us to gain valuable feedback leading to rapid improvement.

SCARLETRED is the worldwide leader in standardized skin imaging and AI powered objective skin analysis. We develop and deliver cutting edge software products and services to biopharma-, biotech- , cosmetics companies, clinical research organisations and health care experts. Our certified, ICH-GCP and EU-GDPR compliant mobile medical device software Scarletred® Vision is the first digital solution solving the problem of lacking standardization and subjective visual skin assessment in pre-clinical, clinical, and post-marketing studies. The highly scalable software platform works infrastructure as well as location independent and enables on-site and home-based monitoring of dermatologic disease as well as digital analysis of skin drug related effects. It it easy to use and reduces development time and opportunity cost in clinical RnD projects. Our digital Products and Services are delivered worldwide from our offices in Europe and USA via flexible Software as a Service (SaaS) agreements.

SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVE’s state of the art HyperVue™ Imaging System combines next generation DeepOCT™ images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events. For more information and complete indications for use, please visit www.spectrawave.com.

Advancing cerebrovascular care through groundbreaking neuro intravascular imaging and AI technologies.